OpenEvidence Hits $15B Valuation, Pivots to Oncology Drug Development

Key points

• OpenEvidence raised $250 million at a $15 billion valuation, up from $12 billion in January 2026.
• The company plans to develop its own oncology therapies, with the first drug entering clinical trials before year-end.
• A partnership with Memorial Sloan Kettering integrates OpenEvidence into Epic workflows and incorporates the OncoKB database.
• OpenEvidence is expanding into approximately 100 low- and middle-income countries via a partnership with Anthropic.
• The startup has raised over $1 billion in the past year from investors including Sequoia Capital, Nvidia, and Thrive Capital.

Background

OpenEvidence, founded in 2022 by Daniel Nadler and Zachary Ziegler, has rapidly scaled from a medical search tool to a major healthcare AI player. Previous coverage noted a broader trend of AI leaders pivoting toward science and biotech, such as former OpenAI executives launching AI-science startups. OpenEvidence’s trajectory mirrors this shift, moving from information retrieval to active drug discovery and global health infrastructure.

How outlets are covering it

Business Insider highlights the funding round and potential M&A interest, noting OpenEvidence could be an acquisition target for AI giants seeking healthcare footholds. Digital Health Wire emphasizes the strategic pivot to drug development and the quiet nature of the funding announcement, contrasting it with the company’s previous high-profile raises. Refresh Miami focuses on the expansion beyond search into oncology and global access, framing the move as a response to intensifying competition from companies like Abridge and Doximity. Livemint provides a general overview, citing adoption metrics that show over 40% of US physicians use the platform daily, and details the Anthropic partnership for global deployment.

Why it matters

OpenEvidence’s move into drug development signals a significant shift in healthcare AI, moving from diagnostic support to therapeutic creation. This expansion could reshape the oncology market by leveraging AI for rare cancer trials, while its global partnerships address healthcare disparities in low-income regions. The high valuation reflects investor confidence in AI’s ability to transform medical workflows and drug discovery.

What to watch

OpenEvidence expects to launch its first oncology therapy into clinical trials before the end of 2026, followed by three to five additional candidates in 2027. The company will continue expanding its global footprint through the Anthropic partnership, aiming to provide free clinical decision support in approximately 100 countries. Further integration with hospital systems and precision oncology databases is expected to deepen its market presence.